Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update

IRVINE, Calif., March 28, 2024 — Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a pharmaceutical company historically focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the fourth quarter and year ended December 31, 2023 and provided a business update. Fourth Quarter and Recent Highlights The… Continue reading Reneo Pharmaceuticals Reports Fourth Quarter And Full Year 2023 Financial Results And Business Update

Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)

The STRIDE study did not meet its primary or secondary efficacy endpoint The company to suspend mavodelpar development and implement a workforce reduction IRVINE, Calif., Dec. 14, 2023 — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced its… Continue reading Reneo Pharmaceuticals Announces Results from Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)

Reneo Pharmaceuticals Reports Third Quarter 2023 Financial Results

Topline data results from the pivotal STRIDE study are expected in December 2023 IRVINE, Calif., Nov. 13, 2023 — Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today reported financial results for the third quarter ended September 30, 2023… Continue reading Reneo Pharmaceuticals Reports Third Quarter 2023 Financial Results

Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences

IRVINE, Calif., Nov. 02, 2023 — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company’s management team will participate in the following investor conferences. Jefferies London Healthcare Conference Date: Tuesday, November 14 – Thursday,… Continue reading Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences

Reneo Pharmaceuticals Announces Poster Presentation at Upcoming Scientific Meetings

IRVINE, Calif., Oct. 25, 2023 — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced the company will present a poster titled “Selective peroxisome proliferator-activated receptor (PPAR) delta (δ) agonist, mavodelpar, improves cellular bioenergetics in fibroblasts from… Continue reading Reneo Pharmaceuticals Announces Poster Presentation at Upcoming Scientific Meetings

Reneo Pharmaceuticals Announces Last Patient Last Visit in the Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)

Topline data results from the STRIDE study are expected in December 2023 IRVINE, Calif., Oct. 09, 2023 — Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, announced last patient last visit (LPLV) in the pivotal STRIDE study of mavodelpar… Continue reading Reneo Pharmaceuticals Announces Last Patient Last Visit in the Pivotal STRIDE Study of Mavodelpar in Primary Mitochondrial Myopathies (PMM)

Reneo Pharmaceuticals to Participate in the Jefferies Biotech CNS/Neuro Summit

IRVINE, Calif., Oct. 06, 2023 — Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company’s management team will participate in the Jefferies Biotech CNS/Neuro Summit. Jefferies Biotech CNS/Neuro SummitDate: Wednesday, October 11, 2023 Location:… Continue reading Reneo Pharmaceuticals to Participate in the Jefferies Biotech CNS/Neuro Summit

Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences

IRVINE, Calif., Aug. 29, 2023 — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare genetic mitochondrial diseases, today announced that the company’s management team will participate at the upcoming healthcare investor conferences. Citi BioPharma ConferenceDate: Wednesday, September 6 – Thursday, September… Continue reading Reneo Pharmaceuticals to Participate in Upcoming Investor Conferences

Reneo Pharmaceuticals Reports Second Quarter 2023 Financial Results

Topline results of the STRIDE study, the pivotal mavodelpar clinical trial in adult patients with primary mitochondrial myopathies (PMM) due to mitochondrial DNA (mtDNA) defects, anticipated in 4Q23 IRVINE, Calif., Aug. 10, 2023 — Reneo Pharmaceuticals, Inc. (Nasdaq: RPHM), a clinical-stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare… Continue reading Reneo Pharmaceuticals Reports Second Quarter 2023 Financial Results

Reneo Pharmaceuticals to Participate in SVB Securities Therapeutics Forum

IRVINE, Calif., June 30, 2023 — Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM), a clinical stage pharmaceutical company focused on the development and commercialization of therapies for patients with rare, genetic, mitochondrial diseases, today announced that the company’s management team will participate at the SVB Securities Therapeutics Forum. SVB Securities Therapeutics ForumDate: Tuesday, July 11th – Wednesday,… Continue reading Reneo Pharmaceuticals to Participate in SVB Securities Therapeutics Forum